1[1]Alberit A, Benvegnu L. Management of hepatitis C. J Hepatol,2003,38(suppl 1): S1014 ～ S118
2[2]Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut,2001,49(Suppl Ⅰ) :S1 ～ S12
3[3]Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribvirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002,51: 864 ～ 869
4[4]Chander G, Sulkowski MS, Jenckes MW. et al. Treatment of chronic hepatitis C: a systemic review. Hepatology, 2002,36 (5 suppl 1 ):S135 ～ S144
5[5]DiCiommo V, Russo P, Rave L, et al. Interferon alpha in the treatment of chronic hepatits C in children: a meta-analysis. J Viral Hepat,2003, 10:210 ～ 214
6[6]Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther,2003,18:1071 ～ 1081
7[7]Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ, 2001,323:1151 ～ 1155
8[8]National Institute of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology, 2002, 36: (5Suppl 1):S3 ～ 20
9[9]Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta analysis. Aliment Pharmacol Ther,2001,15:689～ 698
10[10]Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology, 2000,32: 1131 ～ 1137
5Yuan-Ding Chen,Ming-Ying Liu,Wen-Lin Yu,Jia-Qi Li,Mei Peng,Qing Dai,Xiao Liu Zhen-Quan Zhou From the Central Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, China Kunming Hospital for Infectious Diseases, Kunming 650041, China.Hepatitis C virus infections and genotypes in China[J].Hepatobiliary & Pancreatic Diseases International,2002,1(2):194-201. 被引量：18
